Professor Nico van Zandwijk will speak on the developments in treating malignant mesothelioma, a subject of increasing promise.
In 2007, he joined ADRI after a long career in thoracic oncology in Europe. In 1985, he founded the department of thoracic oncology at the Netherlands Cancer Institute and made major contributions to the identification of prognostic factors in lung cancer and malignant mesothelioma, to chemoprevention studies in lung cancer and major national and international clinical trials.
He served as secretary (1982-1988) and chair (1988-1994) of the EORTC Lung Cancer Cooperative Group. He chaired the Dutch Guidelines Committee for Diagnosis and Treatment of Lung Cancer and State Committees on Asbestos-related diseases, and Asbestos & Lung Cancer of the Dutch Health Council (2002-08). He was a member of the Board of Directors of the International Association for the Study on Lung Cancer (IASLC) (2005-09) and the advisory board of the Thoracic Oncology Section of the French National Cancer Institute (INca) (2006-2008) and co-chaired the (IASLC) World Conference on Lung Cancer 2011 in Amsterdam and is a member of the Core Program Committee for the WCLC 2013 in Sydney.
He is a member of the National Lung Cancer Advisory Group of Cancer Australia and the National Asbestos Management Review Panel. Also, he has authored or co-authored more than 250 peer-reviewed international scientific papers and book chapters and has long-standing collaborations with investigators from other states in Australia, Europe, Canada, the US, Japan and Korea.